[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Fundació Eurecat\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":147},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,88,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100617459","effect-of-agarcollagen-based-compounds-on-osteoarticular-pain-randomized-triple-blind-clinical-trial-100617459",false,"NCT07318896","Effect of Agar\u002FCollagen-based Compounds on Osteoarticular Pain: Randomized Triple-blind Clinical Trial","Evaluation of the Effect of Agar and\u002For Collagen Based Compounds on Osteoarticular Pain. A Randomized, Parallel, Placebo Controlled, Triple Blind Clinical Trial (AGARTROSIS)","AGARTROSIS","Inclusion Criteria:\n\n* Men and women between 40 and 70 years of age.\n* Submit a score of 6 to 10 out of 20 on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) knee pain questionnaire.\n* Sign the informed consent form.\n* Know how to read, write, and speak Spanish and\u002For Catalan.\n\nExclusion Criteria:\n\n* Present body mass index (BMI) values \\\u003C18.5 kg\u002Fm\\^2 or ≥30 kg\u002Fm\\^2.\n* Present intolerances or allergies related to Agar-Agar, or any of the components of the products being evaluated, such as collagen or maltodextrin.\n* Take or have taken medications that may affect the study results. This is especially true for those who have been treated with oral or intra-articular corticosteroids within the 4 and 12 weeks prior to screening, respectively, or medications for osteoarthritis at the time of screening.\n* Patients who depend on prescription medications for pain control.\n* Take multivitamin or mineral supplements, collagen derivatives, or supplements containing bioactive compounds that may exert an anti-inflammatory effect, such as turmeric, ginger, omega-3, or polyphenol supplements.\n\n(Individuals who consume multivitamin, mineral, or collagen-derived supplements or supplements will be eligible to participate in the study, provided they are willing to discontinue their intake for at least two weeks prior to the start of the study and throughout the entire study period).\n\n* Be an active smoker or have been one for less than 6 months.\n* Alcohol consumption:\n\n  * Men: Consume 4 or more Standard Drink Units (SDU) daily or SDUs weekly.\n  * Women: Consume 2 or more Standard Drink Units (SDU)\\* daily or SDUs weekly.\n* Have a diagnosis of osteoarthritis, active rheumatoid arthritis, and any inflammatory arthritic condition such as secondary inflammatory arthritis, gout, pseudogout, knee infection, marked angular deformities, or significant injury to the target joint within the 6 months prior to the start of the trial; arthroplasty and joint surgery of the target knee within the 2 years prior to the start of the study.\n* Have any gastrointestinal disease that affects the absorption of the compound and\u002For the study results, such as celiac disease, Crohn's disease, active cancer of any organ of the digestive or renal system, or hepatitis.\n* Be ineligible to participate in the study, according to the pre-screening evaluator's criteria.\n* Have lost 3 kg or more in the last 3 months.\n* Be pregnant or intend to become pregnant.\n* Be breastfeeding.\n* Be unable to follow the study guidelines.\n* Be participating or have participated in a clinical trial involving drug intervention or nutritional intervention within the last 30 days prior to inclusion in the study.","ALL","40 Years","70 Years",{"count":21,"type":22},80,"ESTIMATED","INTERVENTIONAL",[25],"NA","Joints-comprising bone, cartilage, ligaments, and synovial fluid-enable stable daily movement but may deteriorate with age, excess body weight, overuse, injury, or disease. Such degeneration, common from age 40 onward, underlies joint disorders like osteoarthritis, particularly in the knees, hips, hands, and spine, and is a major cause of chronic pain and disability. While antiinflammatory analgesics remain the standard approach to symptom control, they neither cure disease nor regenerate cartilage and can produce significant long-term adverse effects (gastrointestinal, hepatic, renal, and cardiovascular). These limitations motivate interest in natural or complementary strategies with safer profiles.\n\nWithin this context, marine algae, especially agar derived from red seaweed, have attracted attention for potential intestinal, metabolic, and joint benefits, aided by their fiber content. Another promising option is undenatured type II collagen (UC-II), the principal structural component of articular cartilage, whose endogenous production declines with age; clinical studies indicate that a daily intake of 40 mg UC-II can improve mobility, reduce pain, and enhance quality of life in individuals with osteoarthritis or exercise-related joint discomfort. Based on these considerations, an agar-agar supplement has been developed to relieve knee joint symptoms.",[28,29,30,31],"Osteearthritis","Joint Damage","Inflammation","Cartilage Damage",[33,34,35,36],"Agar-Agar","undenatured collagen type II","Joint pain","knee pain","RECRUITING","2025-12-19",{"date":40,"type":41},"2026-01-06","ACTUAL",{"date":43,"type":41},"2025-11-10",{"date":45,"type":22},"2027-02",{"name":47,"class":48},"Fundació Eurecat","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":49},"100594862","effect-of-the-combination-of-pterostilbene-cocrystal-with-silybin-and-nicotinamide-riboside-on-exercise-induced-oxidative-stress-100594862","NCT07024966","Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress","Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on High-Intensity Exercise-Induced Oxidative Stress: A Randomized, Crossover, Placebo-Controlled, Triple-Blind Study","PT-SILAOX","Inclusion Criteria:\n\n* Male participants between 18 and 50 years of age who are amateur runners.\n* Engage in at least 3 continuous running sessions per week, each lasting 60 minutes, which corresponds to a high level of physical activity according to the International Physical Activity Questionnaire (IPAQ).\\*\n* Self-report being able to continuously run for 45 minutes at high intensity without difficulty.\n* Provide signed informed consent prior to participation in the study.\n* Able to read, write, and speak either Catalan or Spanish.\n\n  * High level of physical activity according to the IPAQ: vigorous physical activity (such as running) on at least 3 days per week, with a total energy expenditure ≥1500 MET-min\u002Fweek.\n\nMET value for vigorous activity = 8 × minutes × days per week.\n\nExclusion Criteria:\n\n* Body Mass Index (BMI) ≤ 18 kg\u002Fm² or ≥ 30 kg\u002Fm².\n* Presence of chronic diseases associated with increased oxidative stress, such as diabetes, hypertension, chronic obstructive pulmonary disease (COPD), or neurodegenerative diseases.\n* Personal history of cardiovascular disease, including myocardial infarction, angina pectoris, stroke, or peripheral artery disease.\n* Use of antibiotics within 30 days prior to study entry.\n* Use of medications or vitamin supplements that may interfere with the study supplement and exceed 100% of the recommended daily intake within 30 days prior to the start of the study.\n* Use of polyphenol supplements, herbal extracts, or phytotherapeutic products that may interfere with the study treatment within 30 days prior to study start.\n* Alcohol consumption of 4 or more Standard Drink Units (SDUs) per day or 28 SDUs per week.\\*\n\n  \\*One SDU is defined as 10 grams of alcohol. This corresponds approximately to: 1 glass of wine (120 mL), 1 beer (330 mL), or 1 small spirit (25 mL); 2 SDUs correspond to 1 glass of brandy or liqueur (55 mL), 1 whiskey (70 mL), or a mixed drink (75 mL).\n* Active smoker.\n* Unintentional weight loss of more than 3 kg in the past 3 months.\n* Known food allergies and\u002For intolerances related to the study products.\n* Presence of anemia.\n* Presence of chronic gastrointestinal diseases\\* or cancer.\\*\\*\n\n  \\*Chronic gastrointestinal diseases include those in an active phase that may interfere with nutrient absorption. Common examples include gastritis, hiatal hernia, Crohn's disease, celiac disease, irritable bowel syndrome, diverticulitis, diverticulosis, chronic constipation, and ulcerative colitis.\n\n  \\*\\*Individuals with a history of cancer may be included only if they are in complete remission at the start of the study.\n* Participation in another drug clinical trial or nutritional intervention study within 30 days prior to study inclusion.\n* Inability to follow the study guidelines.",true,"MALE","18 Years","50 Years",{"count":63,"type":22},14,[25],"This study aims to evaluate the effects of the dietary supplement ccPT-SIL-NR, which contains pterostilbene (ccPT), silybin (SIL), and nicotinamide riboside (NR), on oxidative stress markers after a high-intensity exercise session. The primary objective is to assess changes in blood malondialdehyde (MDA) levels.\n\nSecondary objectives include evaluating the effects on oxidative DNA damage (8-OHdG), lipid peroxidation (F2-isoprostanes), total antioxidant capacity (FRAP assay), glutathione ratio (GSH\u002FGSSG), antioxidant enzyme activity (SOD, CAT, GPx), inflammatory markers (hsCRP, MCP-1, IL-6), muscle damage markers (LDH, CK), cortisol levels, renal function (creatinine), and gene expression patterns through transcriptomic analysis.\n\nThe study will include 14 healthy male participants in a randomized, tripple-blind, placebo-controlled, crossover design. Each participant will receive both the ccPT-SIL-NR supplement and placebo for 14 days each, separated by a washout period of at least one week. A high-intensity exercise test will be performed at the end of each supplementation period. Total study duration per participant will be a minimum of 6 weeks.",[67,68,69],"Oxidative Stress","Physical Activity","Antioxidant Effect",[67,71,72,73,74,75,76,77,78,79],"High-intensity exercise","Pterostilbene","Antioxidant supplement","Nutraceutical","Crossover trial","Exercise recovery","Nutritional intervention","Polyphenols","Cocrystal","2025-08-26",{"date":82,"type":41},"2025-08-27",{"date":84,"type":41},"2025-08-01",{"date":86,"type":22},"2025-11",{"name":47,"class":48},{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":58,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":23,"phases":98,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},"100548572","effect-of-a-grape-seed-proanthocyanidin-extract-gspe-on-ldl-cholesterol-levels-in-rotating-night-shift-workers-100548572","NCT06422741","Effect of a Grape Seed Proanthocyanidin Extract (GSPE) on LDL Cholesterol Levels in Rotating Night Shift Workers","Effect of a Grape Seed Proanthocyanidin Extract (GSPE) on LDL Cholesterol Levels in Rotating Night Shift Workers With Moderate Hypercholesterolemia. Randomized, Crossover, Controlled and Triple Blind Study.(CIRCAFENOL)","CIRCAFENOL","Inclusion Criteria:\n\n* Men and women aged 18 years or older.\n* Follow a rotating night shift work schedule\\* for at least one year before the start of the study.\n\n  \\* shift workers with at least 5 night shifts per month alternating with day and\u002For afternoon shifts, with a seniority equal to or greater than one year.\n* Have no intention of changing the work shift during the course of the study.\n* Circulating LDL-C levels between 116 -190 mg\u002FdL\\*, without pharmacological treatment with antihypertensives and\u002For lipid-lowering agents.\n\n  \\*Values of 116 to 190 mg\u002Fdl indicate moderate alteration in the lipid profile and a greater risk of suffering from cardiovascular diseases, according to the European Society of Cardiology, and the European Society of Atherosclerosis.\n* Have signed the informed consent before starting the study.\n* Know how to read, write and speak in Catalan or Spanish\n\nExclusion Criteria:\n\n* BMI values \\> 30 kg\u002Fm2\n* Take supplements, multivitamin supplements (Vit.D, Vit. E and Vit.C), mineral supplements (Zinc, Selenium), essential fatty acids (omega-3), polyphenols, natural plant extracts, or phytotherapeutic products that interfere with the treatment under study.\n* Consumption of alcoholic beverages:\n\n  * Men: consume 4 or more Standard Beverage Units daily or 28 Standard Beverage Units weekly.\n  * Women: Consume 2 or more Standard Beverage Units daily or 17 Standard Beverage Units weekly.\n* Be an active smoker.\n* Having lost more than 3 kg of weight in the last 3 months.\n* Present food intolerances and\u002For allergies related to the study products, such as hypersensitivity to cellulose or proanthocyanidins.\n* Present any chronic or autoimmune disease in clinical manifestation that may affect the results of the study such as diabetes (type I or II), cardiovascular disease, chronic kidney disease, hyper or hypothyroidism, chronic gastrointestinal diseases or cancer.\n* Present familial hypercholesterolemia.\n* Present hypertension (Systolic ≥140 mmHg; Diastolic ≥90 mmHg)\n* Present any previous cardiovascular disease defined as myocardial infarction, angina pectoris, stroke or peripheral arterial disease.\n* Individuals with treatment in the last 3 months before the start of the study with lipid-lowering, antidiabetic and\u002For antihypertensive drugs, or other drugs that may interfere with the results of the study.\n* Taking supplements with polyphenol components or those aimed at lipid or blood pressure control in the last 3 months before the start of the study or during participation in the study.\n* Follow a diet to lose weight, or very restrictive types of eating, such as intermittent fasting, ketogenic diet, etc.\n* Being pregnant or intending to become pregnant.\n* Being breastfeeding.\n* Be participating or have participated in a clinical trial with medications or nutritional intervention study in the last 30 days before inclusion in the study.\n* Suffering from eating disorders or psychiatric disorders.\n* Being unable to follow study guidelines.",{"count":97,"type":22},22,[25],"The physiological processes of the body present daily oscillations called circadian rhythm. The circadian rhythm is essential for maintaining the vital functions of organisms, intervening directly and indirectly in a multitude of key processes, such as hormone secretion, cycles of activity and rest throughout the day, body temperature, the metabolism or absorption, processing and detoxification of nutrients. There are factors such as certain work schedules, prolonged exposure to screens, certain eating patterns or social jetlag, which have a negative impact on the circadian rhythm, causing its disruption and favoring the appearance of health alterations. Thus, there is evidence that associates night shift work with a higher incidence of risk factors for developing metabolic syndrome and cardiovascular diseases, including obesity, elevated blood levels of glucose, triglycerides, and low-density lipoprotein cholesterol (LDL-C), as well as lower levels of high-density lipoprotein cholesterol (HDL-C). In addition, disorders in the sleep cycle are associated with the development of hypertension and type 2 diabetes.\n\nSeveral previous studies show that a grape seed proanthocyanidin extract (GSPE) has beneficial effects on different parameters by restoring the circadian rhythm.",[101,102,103],"Cardiovascular Diseases","Circadian Rhythm Sleep Disorder, Shift Work Type","Cholesterol Level, High",[105,106,107,108,78],"Proanthocyanidins","Circadian Rhythm","Metabolic Syndrome","Melatonin",{"date":82,"type":41},{"date":111,"type":41},"2024-10-28",{"date":113,"type":22},"2026-02",{"name":47,"class":48},2,{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":58,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":23,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":115},"100499617","effect-of-methylcobalamin-and-cyanocobalamin-consumption-on-vitamin-b12-nutritional-status-100499617","NCT05785585","Effect of Methylcobalamin and Cyanocobalamin Consumption on Vitamin B12 Nutritional Status","Effect of Methylcobalamin and Cyanocobalamin Consumption on Vitamin B12 Nutritional Status in Vegetarians With Marginal Vitamin B12 Deficiency. Randomized, Parallel, Placebo-Controlled, Triple-Blind Clinical Trial.","NORMB12","Inclusion Criteria:\n\n* Men and women aged 18 years or older who follow a vegetarian diet.\n* Present serum vitamin B12 levels of 148-221 pmol\u002FL and absence of symptoms associated with vitamin B12 deficiency.\n* Sign the informed consent.\n* Read, write and speak Catalan or Spanish.\n\nExclusion Criteria:\n\n* Present diagnosed diseases that may interfere with vitamin B12 markers, including gastrointestinal diseases (such as inflammatory bowel disease, celiac disease, ileal resection, Crohn's disease, constipation or atrophic gastritis), pancreatic diseases, kidney diseases, liver diseases, diabetes, cardiovascular diseases, pernicious anemia and cancer.\n* Medical history of abdominal surgery that may influence the absorption of vitamin B12 (such as bariatric surgery).\n* Being on hemodialysis treatment.\n* Present values of body mass index ≤ 18.5 kg\u002Fm\\^2 or ≥ 35 kg\u002Fm\\^2.\n* Present anemia (hemoglobin ≤ 13 g\u002FdL in men and ≤ 12 g\u002FdL in women).\n* Having consumed or consume vitamin B12 or folate supplements for more than 2 months before inclusion in the study.\n* Have taken medications that affect the absorption and therapeutic response of vitamin B12 (such as methotrexate, metformin, proton pump inhibitors, H2 receptor antagonists, histamine, nitrous oxide, colchicine, neomycin, biguanides, cholestyramine, aminosalicylic acid, chloramphenicol and other bone marrow depressants) one month before inclusion in the study.\n* Be a smoker or ex-smoker in the last 6 months before inclusion in the study.\n* Take 2 or more Standard Beverage Units (SBU) daily or 17 SBU weekly for women, or take 4 or more SBU daily or 28 SBU weekly for men.\n* Present allergy or intolerance to the study products (microcrystalline cellulose, vitamin B12 or cobalt).\n* Being pregnant or intending to become pregnant.\n* Being in breastfeeding period.\n* Participate in or have participated in a clinical trial or nutritional intervention study in the last 30 days before inclusion in the study.",{"count":125,"type":22},54,[25],"Vitamin B12 (B12, Cobalamin) is an essential micronutrient that humans are not capable of synthesizing and therefore must be ingested through food. In nature, B12 is basically only present in foods of animal origin.\n\nB12 deficiency is a clinically important condition that is associated with several metabolic disorders such as megaloblastic anemia, hyperhomocysteinemia, and cardiovascular, cerebrovascular, and neurological disorders. Therefore an optimal intake of B12 is important.\n\nB12 deficiency occurs when B12 stores are depleted due to inadequate dietary intake or impaired absorption of B12. Because B12 is only present in foods of animal origin, following an unbalanced vegetarian diet is associated with increased risk of developing nutritional deficiencies due to the exclusion of meat and fish from their diet, including vitamin B12 deficiency.\n\nThere are a variety of forms of vitamin B12 used in vitamin B12 supplements. All these forms share the structure of Cobalamin but contain different ligands. Cyanocobalamin (CNCbl) is a synthetic, stable, and inexpensive form widely used in B12 supplements. MethylCobalamin (MeCbl) is a physiological form of cobalamin, called metabolically active form of vitamin B12. Interest in substituting CNCbl form with the physiological form MCbl has recently increased, assuming that it will be more effective.\n\nThe main objective of the study is to evaluate the effect of Methylcobalamin consumption, compared to Cyanocobalamin consumption, on the nutritional status of vitamin B12 in a vegetarian population with marginal vitamin B12 deficiency.\n\nThe secondary objectives of the study are to evaluate the effects of Methylcobalamin consumption, compared to Cyanocobalamin consumption, on markers of vitamin B12 deficiency: Holotranscobalamin, Methylmalonic acid, Homocysteine and 4cB12.\n\nDuring the study there will be 8 visits: a preselection visit (V0; day -7) and 7 study visits during the consumption of the treatments, which will take place on the first day of the study (V1; day 1), after 8 days of treatment (V2; day 8), at 15 days of treatment (V3; day 15), at 29 days of treatment (V4; day 29), at 43 days of treatment (V5; day 43), at 64 days of treatment (V6; day 64), and at 85 days of treatment (V7; day 85).",[129],"Vitamin B12 Nutritional Deficiency",[131,132,133,134,135,136,137,138],"Vitamin B12","Methylcobalamin","Cyanocobalamin","Vegetarians","Holotranscobalamin","Methylmalonic acid","Homocysteine","4cB12","2024-10-29",{"date":141,"type":41},"2024-10-30",{"date":143,"type":41},"2023-09-09",{"date":145,"type":22},"2025-09",{"name":47,"class":48},""]